DDInter1256 DDInter1628
A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Nafcillin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Nafcillin {u} (Compound) causes {v} (Side Effect) Neutropenia
Neutropenia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Nafcillin {u} (Compound) resembles {v} (Compound) Flucloxacillin
Flucloxacillin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Nafcillin {u} (Compound) resembles {v} (Compound) Amoxicillin
Amoxicillin {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Nafcillin {u} (Compound) resembles {v} (Compound) Phenoxymethylpenicillin
Phenoxymethylpenicillin {u} (Compound) downregulates {v} (Gene) KLHDC2
KLHDC2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Nafcillin {u} (Compound) resembles {v} (Compound) Phenoxymethylpenicillin
Phenoxymethylpenicillin {u} (Compound) downregulates {v} (Gene) PRPF4
PRPF4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Nafcillin {u} (Compound) resembles {v} (Compound) Benzylpenicillin
Benzylpenicillin {u} (Compound) upregulates {v} (Gene) CPSF4
CPSF4 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Nafcillin {u} (Compound) resembles {v} (Compound) Benzylpenicillin
Benzylpenicillin {u} (Compound) downregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Nafcillin {u} (Compound) resembles {v} (Compound) Piperacillin
Piperacillin {u} (Compound) upregulates {v} (Gene) PIGB
PIGB {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Nafcillin {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) covaries with {v} (Gene) MBOAT7
MBOAT7 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Nafcillin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Nafcillin (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Ruxolitinib (Compound)
Nafcillin (Compound) resembles Flucloxacillin (Compound) and Flucloxacillin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Nafcillin (Compound) resembles Amoxicillin (Compound) and Amoxicillin (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Ruxolitinib (Compound)
Nafcillin (Compound) resembles Phenoxymethylpenicillin (Compound) and Phenoxymethylpenicillin (Compound) downregulates KLHDC2 (Gene) and KLHDC2 (Gene) is downregulated by Ruxolitinib (Compound)
Nafcillin (Compound) resembles Phenoxymethylpenicillin (Compound) and Phenoxymethylpenicillin (Compound) downregulates PRPF4 (Gene) and PRPF4 (Gene) is upregulated by Ruxolitinib (Compound)
Nafcillin (Compound) resembles Benzylpenicillin (Compound) and Benzylpenicillin (Compound) upregulates CPSF4 (Gene) and CPSF4 (Gene) is downregulated by Ruxolitinib (Compound)
Nafcillin (Compound) resembles Benzylpenicillin (Compound) and Benzylpenicillin (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) is downregulated by Ruxolitinib (Compound)
Nafcillin (Compound) resembles Piperacillin (Compound) and Piperacillin (Compound) upregulates PIGB (Gene) and PIGB (Gene) is downregulated by Ruxolitinib (Compound)
Nafcillin (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) covaries with MBOAT7 (Gene) and MBOAT7 (Gene) is downregulated by Ruxolitinib (Compound)